Orlistat
From Wikipedia, the free encyclopedia
Orlistat
Systematic (IUPAC) name
1-(3-hexyl-4-oxo-oxetan-2-yl)tridecan-2-yl 2-formylamino-4-methyl-pentanoate
Identifiers
CAS number
96829-58-2
ATC code
A08AB01
PubChem
3034010
DrugBank
APRD00255
Chemical data
Formula
C29H53NO5
Mol. mass
495.735 g/mol
Pharmacokinetic data
Bioavailability
Negligible[1]
Protein binding
>99%
Metabolism
In the GI tract
Half life
1 to 2 hours
Excretion
Fecal
Therapeutic considerations
Licence data
EU, US
Pregnancy cat.
B1(AU) B(US)
Legal status
Pharmacist Only (S3)(AU) POM(UK) OTC(US)
Routes
Oral
Orlistat (marketed under the trade name Xenical by Roche; or over-the-counter as alli[2] by GlaxoSmithKline (pronounced /'æla?/, like the English word "ally")—also known as tetrahydrolipstatin—is a drug designed to treat obesity.[3] Its primary function is preventing the absorption of fats from the human diet, thereby reducing caloric intake. It is intended for use in conjunction with a physician-supervised reduced-calorie diet.
Orlistat is the saturated derivative of lipstatin—a potent natural inhibitor of pancreatic lipases isolated from the bacterium Streptomyces toxytricini.[4] However, due to simplicity and stability, orlistat rather than lipstatin was developed into an anti-obesity drug.[5]
